A composition for culturing peripheral blood monocyte-derived regulatory T cells includes at least one antibody selected from the group consisting of anti-CD2, anti-CD3, anti-CD7, anti-CD8, anti-CD28, anti-CD30L, anti-CD40, anti-CD70, anti-CD80, anti-CD83, and anti-CD86; at least one cytokine selected from the group consisting of interleukin-2, interleukin-4, interleukin-7, interleukin-12, interleukin-15, interleukin-34, and TGF-; and superoxide dismutase. A regulatory T cell culturing method using this composition is also provided. The regulatory T cells according obtained by this method can be utilized for treatment of autoimmune diseases.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

The present invention provides a method for maintaining a continuous epithelial structure of a retinal tissue including culturing the retinal tissue in a medium comprising a methyl group donor or a substrate of the methyl group donor at a concentration at which cell differentiation of a neural retinal progenitor cell is suppressed, and a neurite extension inhibitor at a concentration at which neurite extension is suppressed.

Provided is a method for promoting generation of a mitochondria-containing microvesicle and a treating method thereof. Specifically, provided is a method for promoting generation of the mitochondria-containing microvesicle with a combination of a mitochondrial generation promoting factor and an extracellular vesicle generation promoting factor. Also provided is a method for generating an extracellular vesicle composition, comprising: co-culturing cells having mitochondria with the mitochondrial generation promoting factor and the extracellular vesicle generation promoting factor to obtain the extracellular vesicle composition rich in the mitochondria-containing microvesicle. Adding the above factors may promote the cells to generate the mitochondria-containing microvesicle. The collected mitochondria are encapsulated by the microvesicle, and therefore can be easily stored and transferred into the cells. Also provided are an isolated extracellular vesicle composition, a pharmaceutical composition comprising the same, and a method for treating diabetes and/or renal injury by administering a medicine comprising the same.

The present invention can provide a pharmaceutical composition for treating wound repair and a preparation method thereof. The pharmaceutical composition at least includes an extracellular vesicle, insulin, and a plurality of growth factors, wherein the concentration of the extracellular vesicle in the pharmaceutical composition is (57.533.79)10.sup.8 particles/mL; the concentration of the insulin in the pharmaceutical composition is 34,870.837,335.13 mU/L; these growth factors are ANGPTL4, HGF, G-CSF, PDGF-AA, VEGF-A, IL-18BPa, COMP, MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-10, and MMP-12; and the extracellular vesicle contains a CLU protein, a TIMP1 protein and a YWHAB protein.